Sei Investments Co. Reduces Position in Moderna, Inc. (NASDAQ:MRNA)

Sei Investments Co. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 12.5% in the fourth quarter, HoldingsChannel reports. The firm owned 61,859 shares of the company’s stock after selling 8,835 shares during the period. Sei Investments Co.’s holdings in Moderna were worth $2,572,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRNA. American Century Companies Inc. boosted its stake in shares of Moderna by 2.7% during the 4th quarter. American Century Companies Inc. now owns 44,619 shares of the company’s stock valued at $1,855,000 after buying an additional 1,187 shares during the last quarter. Quantbot Technologies LP boosted its stake in Moderna by 315.3% during the 4th quarter. Quantbot Technologies LP now owns 9,307 shares of the company’s stock valued at $387,000 after acquiring an additional 7,066 shares during the last quarter. Northwest & Ethical Investments L.P. boosted its stake in Moderna by 209.0% during the 4th quarter. Northwest & Ethical Investments L.P. now owns 43,466 shares of the company’s stock valued at $1,807,000 after acquiring an additional 29,398 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Moderna by 14.3% in the 4th quarter. Teacher Retirement System of Texas now owns 101,382 shares of the company’s stock worth $4,215,000 after purchasing an additional 12,651 shares during the last quarter. Finally, Privium Fund Management B.V. raised its stake in shares of Moderna by 103.7% in the 4th quarter. Privium Fund Management B.V. now owns 82,476 shares of the company’s stock valued at $3,429,000 after purchasing an additional 41,994 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MRNA. Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Berenberg Bank boosted their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. JPMorgan Chase & Co. dropped their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Friday, March 21st. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $59.00.

Moderna Price Performance

Shares of MRNA stock opened at $25.11 on Friday. Moderna, Inc. has a 12-month low of $23.76 and a 12-month high of $170.47. The firm has a market capitalization of $9.71 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23. The business has a 50 day simple moving average of $33.55 and a 200 day simple moving average of $43.01.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.